Table 4: FDA approved indications of angiogenesis inhibitors.

Drug name

FDA approval year

Prescribing considerations for TE risk

 Indications

1. Afatinib

2013

No

·         Metastatic NSCLC with EGFR exon mutations

2. Axitinib

2012

Yes

·         Advanced Renal Cell Carcinoma (RCC) after failure of one prior systemic therapy

3. Bevacizumab

2004

Yes

·         First‐ or second‐line treatment for mCRC as a combination agent with 5‐Fluorouracil (5‐FU)

·         Progression of glioblastoma on prior other therapy

·         As a combination agent for

·         Persistent, recurrent, or metastatic carcinoma of the cervix

·         Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer

·         Metastatic RCC

·         Recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

4. Bosutinib

2012

No

·         Philadelphia Chromosome‐Positive (Ph+) Chronic Myelogenous Leukemia (CML)

5. Cabozantinib

2012

Yes

·         Progressive, metastatic Medullary Thyroid Cancer (MTC)

6. Ceritinib

2014

No

·         Metastatic NSCLC, Anaplastic Lymphoma Kinase (ALK)‐positive

7. Cetuximab

2004

No

·         EGFR‐expressing wild‐type K‐RAS mCRC

·         Squamous cell carcinoma of the head and neck

8. Crizotinib

2011

No

·         Anaplastic Lymphoma Kinase (ALK)‐positive metastatic NSCLC

9. Dasatinib

2006

No

·         Newly diagnosed chronic phase Ph+ CML

·         Ph+ CML chronic, accelerated, or myeloid or lymphoid blast phase with resistance or intolerance to prior therapy including imatinib

·         Ph+ ALL with resistance or intolerance to prior therapy

10. Erlotinib

2004

Yes

·         NSCLC with EGFR exon mutations

·         Progressive locally advanced or metastatic NSCLC

·         Locally advanced, unresectable or metastatic pancreatic cancer

11. Gefitinib

2015

No

·         Metastatic NSCLC with EGFR exon mutations

12. Ibrutini b

2013

No

·         Mantle Cell Lymphoma (MCL)

·         Unresponsive Chronic Lymphocytic Leukemia (CLL)

·         CLL with 17p deletion

·         Waldenström's Macroglobulinemia Lymphoma (MCL)

13. Imatinib

2001

No

·         Newly diagnosed chronic phase Ph+ CML

·         Blast crisis, accelerated phase, or chronic phase and relapsed or refractory Ph+ CML

·          Newly diagnosed Ph+ ALL in pediatric patients

·         Myelodysplastic/myeloproliferative diseases with PDGFR gene re‐arrangements, in adult patients

·         Aggressive systemic mastocytosis without or unknown c‐Kit mutation

·         Hypereosinophilic syndrome and/or chronic eosinophilic leukemia

·         Dermatofibrosarcoma protuberans unresectable, recurrent and/or metastatic

·         Malignant gastrointestinal stromal tumors Kit (CD117) positive unresectable and/or metastatic

·         Adjuvant treatment for Kit (CD117) positive Gastrointestinal Stromal Tumor (GIST) after complete gross resection

14. Lapatinib

2007

No

·         Advanced or metastatic breast cancer with over expression of Human Epidermal Growth Factor Receptor 2 (HER2)

15. Nilotinib

2007

Yes

·         Newly diagnosed chronic phase and resistant or intolerant chronic and accelerated phases of Ph+ CML

16. Panitumumab

2006

Yes

·         Wild‐type KRAS mCRC

17. Pazopanib

2009

Yes

·         Advanced RCC

·         Advanced Soft Tissue Sarcomas (STS)

18. Ponatinib

2012

Yes

·         T315I‐positive CML (chronic phase, accelerated phase, or blast phase) or T315Ipositive Ph+ ALL

·         Chronic phase, accelerated phase, or blast phase CML or Ph+ ALL for whom no other TKI therapy is indicated

19. Ramucirumab

2014

Yes

·         Progressive advanced or metastatic, gastric or gastro‐esophageal junction adenocarcinoma

·         Progressive metastatic NSCLC

·         Progressive mCRC

20. Regorafenib

2012

Yes

·         Resistant or progressive mCRC

·         Progressive locally advanced, unresectable or metastatic GIST

21. Ruxolitinib

2011

No

·         Intermediate or high‐risk myelofibrosis, including primary myelofibrosis, postpolycythemia including primary myelofibrosis, postpolycythemia vera myelofibrosis and postessential vera myelofibrosis and postessential thrombocythemia myelofibrosis

·         Polycythemia vera in patients with inadequate response to or who are intolerant of hydroxyurea

22. Sorafenib

2005

Yes

·         Unresectable Hepato Cellular Carcinoma (HCC)

·         Advanced RCC

·         Radioactive iodine treatment refractive locally recurrent or metastatic, progressive, DTC

23. Sunitinib

2006

No

·         Progressive GIST or GIST in patients intolerant to imatinib

·         Advanced RCC

·          Unresectable locally advanced or metastatic, progressive, well‐differentiated pancreatic neuroendocrine tumors

24. Vandetanib

2011

Yes

·         Symptomatic or progressive, unresectable locally advanced or metastatic MTC

25. Ziv‐Aflibercept

2012

Yes

·         Resistant or progressive mCRC